First, although we found that MS had the potential to treat asthma by inhibiting the NF-κB and p38 MAPK signaling, which was partially reversed by anti-CD25 antibody treatment, more mechanisms remain to be elucidated. The gene discussed is NFKB1; the disease is asthma.